Precision AQ is the commercialization partner of choice for biopharma innovators, market access leaders, and brand strategists. With over 1,200 experts across the globe, the company helps pharmaceutical and biotech clients navigate the complexities of commercialization across a product's entire lifecycle - from early pipeline to post-launch optimization. Precision AQ turns data chaos into clarity by integrating technology, deep expertise, and strategic guidance to make access to life-changing medicines actionable and precise.
Formally reintroduced as Precision AQ in May 2024, with AQ standing for "Access Quotient," the company represents the convergence of data and human insight - where IQ meets EQ. Their comprehensive services span value and access, medical communications, investor relations, brand strategy and marketing, and data solutions. Formerly known as Precision Value & Health, the organization operates under the Precision Medicine Group umbrella and has supported launches and label expansions for a significant portion of FDA-approved drugs. The company's team includes former access decision-makers, clinicians, scientists, strategists, and communications professionals who architect leading solutions that deliver new pathways for life-changing medicine.